Effects of KT-362, a sarcolemmal and intracellular calcium antagonist, on calcium transients of cultured neonatal rat ventricular cells: A comparison with gallopamil and ryanodine

Cardiovascular Drugs and Therapy

Volumn 10, Issue 6, 1997, Pages 667-675

  Tatsukawa, Youichi ^a   Arita, Makoto ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Calcium transient; Cultured rat ventricular cells; D 600; Fura 2; Gallopamil; KT 362; Ryanodine; Sarcoplasmic reticulum

Indexed keywords

5 [N (3,4 DIMETHOXYPHENETHYL) BETA ALANYL] 2,3,4,5 TETRAHYDRO 1,5 BENZOTHIAZEPINE HYDROGEN FUMARATE; CALCIUM ANTAGONIST; CALCIUM CHANNEL; FURA 2; GALLOPAMIL; RYANODINE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; FEMALE; HEART CELL CULTURE; HEART MUSCLE CELL; MALE; MICROFLUOROMETRY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOPLASMIC RETICULUM;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; FEMALE; GALLOPAMIL; HEART VENTRICLES; MALE; RATS; RATS, WISTAR; RYANODINE; SARCOLEMMA; THIAZEPINES;

EID: 0030965447     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00053023     Document Type: Article

References (31)

1. 2+ inhibitor. Fed Proc 1986;45:803.
2. Farber NE, Gross GJ. Cardioprotective effects of a new vascular intracellular calcium antagonist, KT-362, in the stunned myocardium. J Pharmacol Exp Ther 1989;248: 39-43.
3. Hester R, Shibata S. KT-362 related effects on intracellular calcium release and associated clinical potential, arrhythmias, myocardial ischemia and hypertension. Cardiovasc Drugs Ther 1990;4:1345-1354.
4. 2+ level in the rat aorta. Br J Pharmacol 1991;102:174-178.
5. Shibata S, Wakabayashi S, Satake N, Hester RK, Ueda S, Tomiyana A. Mode of vasorelaxing action of 5-[3-([2-(3,4-dimethoxyphenyl)-ethyl]amino )-1-oxopropyl]-2,3,4,5-tetrahydro-1,5-benzothiazepine fumarate (KT-362), a new intracellular calcium antagonist. J Pharmacol Exp Ther 1987; 240:16-22.
6. Eskinder H, Hillard CJ, Wilke RA, Gross GJ. Effect of KT-362, a putative intracellular calcium antagonist, on norepinephrine-induced contractions and inositol monophosphate accumulation in canine femoral artery. J Cardiovasc Pharmacol 1989;13:502-507.
7. Kodama I, Wakabayashi S, Toyama J, Shibata S, Yamada K. Electrophysiological effects of KT-362, a new antiarrhythmic agent with vasodilating action, on isolated guinea pig ventricular muscle. J Cardiovasc Pharmacol 1988;11: 687-693.
8. Cheng YN, Kiyosue T, Arita M. Effects of KT-362, a new antiarrhythmic agent, on membrane currents of guinea pig ventricular myocytes. J Pharmacol Exper Ther 1993;270: 851-857.
9. Kodama I, Shibata S. Effects of KT-362, a new antiarrhythmic agent with vasodilating action on intracellular calcium mobilization of atrial muscle. J Pharmacol Exp Ther 1991; 258:332-338.
10. Farber NE, Gross GJ. Collateral blood flow following acute coronary artery occlusion, comparison of a new intracellular calcium antagonist (KT-362) and diltiazem. J Cardiovasc Pharmacol 1989b;14:66-72.
11. 2+ transients in cultured rat ventricular cells (abstr). Jpn Circ J 1993;57(Suppl III):1117 (in Japanese).
12. Tatsukawa Y, Arita M, Kiyosue T, Mikuriya Y, Nasu M. A comparative study of effects of isoproterenol and dihydroouabain on calcium transients and contraction in cultured rat ventricular cells. J Mol Cell Cardiol 1993;25: 707-720.
13. Bollon AP, Nath K, Shay JW. Establishment of contracting heart muscle cell cultures. TCA Manual 1977;3:637-640.
14. Timmerman MP, Ashley CC. Fura-2 diffusion and its use as an indicator of transient free calcium changes in single striated muscle cells. FEBS Lett 1986;209:1-8.
15. Noble D, Powell T. The attenuation and slowing calcium signals in cardiac muscle by fluorescent indicators (abstr). J Physiol (Lond) 1990;425:54P.
16. i in single heart cells revealed by fura-2. Science 1987;235:325-328.
17. Roe MW, Lemasters JJ, Herman B. Assessment of Fura-2 for measurements of cytosolic free calcium. Cell Calcium 1990;11:63-73.
18. ++ channel blocking agents on calcium transients and tension development in isolated mammalian heart muscle. Circ Res 1983;52(Suppl I):47-52.
19. Lee KS, Tsien RW. Mechanism of calcium channel blockade by verapamil, D-600, diltiazem and nitrendipine in single dialyzed heart cells. Nature 1983;302:790-794.
20. Zucchi R, Ronca-Testoni S, Limbruno U, Yu G, Galbani P, Ronca G, Mariani M. Effects of gallopamil on cardiac sarcoplasmic reticulum. J Cardiovasc Pharm 1992;20(Suppl 7):S11-15.
21. Sutko JL, Ito K, Kenyon JL. Ryanodine, a modifier of sarcoplasmic reticulum calcium release in striated muscle. Fed Proc 1985;44:2984-2988.
22. Fabiato A. Effects of ryanodine in skinned cardiac cells. Fed Proc 1985;44:2970-2976.
23. McGrew SG, Wolleben C, Siegl P, Inui M, Fleischer S. Positive cooperativity of ryanodine binding to the calcium release channel of sarcoplasmic reticulum from heart and skeletal muscle. Biochemistry 1989;28:1686-1691.
24. 2+ release channel. Am J Physiol 1987;253:C364-C368.
25. Hansford RG, Lakatta EG. Ryanodine releases calcium from sarcoplasmic reticulum in calcium-tolerant rat cardiac myocytes. J Physiol (Lond) 1987;390:453-467.
26. Dubell WH, Houser SR. Rest decay of calcium transients and contractility in feline ventricular myocytes. Am J Physiol 1990;259:H395-H402.
27. 2+ release channel of sarcoplasmic reticulum. J Biol Chem 1986;261:6300-6306.
28. Buljibasic N, Marijic J, Stowe DF, Gross GJ, Kampine JP, Bosnjak ZJ. Comparative cardiac effects of KT-362 and verapamil in isolated hearts: Correlation to calcium channel current depression. J Cardiovasc Pharmacol 1991;18: 594-604.
29. Kiyosue T, Ito M, Cheng Y-N, Saikawa T, Arita M. KT-362, a vasodilating and antiarrhythmic agent. Cardiovasc Drug Rev (in press).
30. Kahn MD, Wittinchan DJ, Wiesner K. Effects of ryanodine in normal dogs and in those with digitalis induced arrhythmias. Am J Cardiol 1964;14:658-668.
31. Lynch JJ, Rahwann RG, Lucchesi BR. Antifibrillatory actions of bepridil and buthyl-MDI, two intracellular calcium antagonists. Eur J Pharmacol 1985;111:9-15.